Myriad Genetics partners with Positive Bioscience for cancer treatment
Myriad Genetics has forged a partnership with Positive Bioscience to develop molecular genomic based cancer testing in India
US-based molecular diagnostic firm Myriad Genetics has partnered with Positive Bioscience to develop molecular genomic testing in India for preventive cancer treatment. Molecular genomic testing will screen patients for cancer risks, and thus enable preventive measures by helping families of cancer patients to take precaution before the health catastrophe hits them.
As reported by PTI, all testing will be carried out at Myriad's labs in USA and Germany, the companies said in a statement. However, no financial details of the alliance between the two companies have been shared so far.
"Indian patients can now access tests such as BRACAnalysis to identify the risk of developing breast and ovarian cancer, colaris for hereditary colorectal cancer and myRisk test to assess the risk of developing eight cancers," Myriad Genetics International Operations Executive Vice-President Gary King said.
He added, "Our prognostic tests such as EndoPredict for breast cancer and Prolaris for prostate cancer will help to avoid both the over-treatment and under-treatment of patients and personalise patient care while reducing the economic burden of treatment."
Positive Bioscience CEO Samarth Jain said, "These tests will help patients by providing insights into potential healthcare challenges they may encounter and improve the quality of their lives."
Through this partnership, Positive Bioscience aims to reach millions of people in the country who are at higher risk of cancer and improve their quality of life, he added.
US-based molecular diagnostic firm Myriad Genetics has partnered with Positive Bioscience to develop molecular genomic testing in India for preventive cancer treatment. Molecular genomic testing will screen patients for cancer risks, and thus enable preventive measures by helping families of cancer patients to take precaution before the health catastrophe hits them.
As reported by PTI, all testing will be carried out at Myriad's labs in USA and Germany, the companies said in a statement. However, no financial details of the alliance between the two companies have been shared so far.
"Indian patients can now access tests such as BRACAnalysis to identify the risk of developing breast and ovarian cancer, colaris for hereditary colorectal cancer and myRisk test to assess the risk of developing eight cancers," Myriad Genetics International Operations Executive Vice-President Gary King said.
He added, "Our prognostic tests such as EndoPredict for breast cancer and Prolaris for prostate cancer will help to avoid both the over-treatment and under-treatment of patients and personalise patient care while reducing the economic burden of treatment."
Positive Bioscience CEO Samarth Jain said, "These tests will help patients by providing insights into potential healthcare challenges they may encounter and improve the quality of their lives."
Through this partnership, Positive Bioscience aims to reach millions of people in the country who are at higher risk of cancer and improve their quality of life, he added.
Next Story